{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:50:16Z","timestamp":1792018216726,"version":"4.4.0"},"reference-count":0,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2003,11,21]],"date-time":"2003-11-21T00:00:00Z","timestamp":1069372800000},"content-version":"vor","delay-in-days":2456,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1997,3]]},"abstract":"<jats:p> <jats:italic>Aims<\/jats:italic>\u2007Our previous studies using <jats:italic>in vitro<\/jats:italic> hepatic microsomal preparations suggested that the hepatic metabolism of quinine to form the major metabolite 3\u2010hydroxyquinine is most likely catalysed by human P450 3A (CYP3A). The present study was carried out to investigate the kinetics and to identify and further characterise the human liver CYP isoforms involved in the metabolism of quinine.<\/jats:p><jats:p> <jats:italic>Methods<\/jats:italic>\u2007<jats:italic>In vitro<\/jats:italic> human microsomal techniques were employed.<\/jats:p><jats:p> <jats:italic>Results<\/jats:italic>\u2007The mean apparent <jats:italic>K<\/jats:italic><jats:sub>m<\/jats:sub> value for 3\u2010hydroxyquinine formation was 83\u00b119 (s.d.)\u2003\u03bcm, ranging from 57\u2003\u03bcm to 123\u2003\u03bcm in microsomes from ten human livers. There was a 6.7\u2010fold variation in <jats:italic>V<\/jats:italic><jats:sub>max<\/jats:sub> values (mean 547\u00b1416\u2003pmol min<jats:sup>\u22121<\/jats:sup>\u2003mg<jats:sup>\u22121<\/jats:sup>\u200a). Quinine 3\u2010hydroxylation was inhibited by the specific CYP3A inhibitors, troleandomycin, midazolam and erythromycin. Inhibitors selective for CYP1A1\/2, CYP2D6, CYP2E1, CYP2C9\/10 or CYP2C19 had little or no effect on quinine 3\u2010hydroxylation. Using microsomes from a panel of livers, significant correlations were found only between 3\u2010hydroxyquinine activity and other CYP3A activities (caffeine 8\u2010oxidation, omeprazole sulphoxidation, midazolam 1\u2032\u2010hydroxylation and midazolam 4\u2010hydroxylation) and immunoreactive CYP3A content. There were no statistically significant correlations with activities selective for CYP1A2, CYP2C9 and CYP2E1. Competitive inhibition of quinine 3\u2010hydroxylation was observed with a substrate known to be specifically metabolized by human CYP3A, i.e. midazolam, with an apparent <jats:italic>K<\/jats:italic><jats:sub>i <\/jats:sub>value of 11.0\u2003\u03bcm.<\/jats:p><jats:p> <jats:italic>Conclusions<\/jats:italic>\u2007The present results strongly indicate that the conversion of quinine to 3\u2010hydroxyquinine is the major metabolic pathway in human liver <jats:italic>in vitro<\/jats:italic> and that the reaction is catalysed by CYP3A isoforms.<\/jats:p>","DOI":"10.1046\/j.1365-2125.1997.00556.x","type":"journal-article","created":{"date-parts":[[2004,12,20]],"date-time":"2004-12-20T19:06:02Z","timestamp":1103569562000},"page":"245-252","source":"Crossref","is-referenced-by-count":60,"title":["Evidence for involvement of human CYP3A in the 3\u2010hydroxylation of quinine"],"prefix":"10.1111","volume":"43","author":[{"given":"H.","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. F.","family":"Coville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. O.","family":"Miners","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. J.","family":"Birkett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wanwimolruk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,12,23]]},"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2125.1997.00556.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1997.00556.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2125.1997.00556.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:46:10Z","timestamp":1694421970000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2125.1997.00556.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,3]]},"references-count":0,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1997,3]]}},"alternative-id":["10.1046\/j.1365-2125.1997.00556.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2125.1997.00556.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,3]]}}}